British Columbia Hepatitis Testers Cohort: HCV Reinfection Rate ~ 2/100 PY Following SVR With DAA Treatment Among Persons Who Inject Drugs

November 8-12, 2019; Boston, Massachusetts
HCV reinfection rates in British Columbia were relatively low following SVR with DAA treatment but were higher among persons who inject drugs vs the overall cohort.
Format: Microsoft PowerPoint (.ppt)
File Size: 211 KB
Released: November 20, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Related Content

Top EASL 2021 studies from Clinical Care Options (CCO) and Stefan Zeuzem: HBV Cure, HCV point-of-care testing and treatment cascade, utility of SVR4, emerging HDV treatments

Stefan Zeuzem, MD Released: July 22, 2021

Top EASL 2021 studies from Clinical Care Options (CCO) and Tarik Asselah: HBV Cure, HCV point-of-care testing and treatment cascade, utility of SVR4, emerging HDV treatments

Tarik Asselah, MD, PhD Released: July 20, 2021

CCO slideset: key viral hepatitis studies EASL 2021, including treatment of HDV, HBV, HCV in in adults and children, linking patients to care, HBV cure, and more

Tarik Asselah, MD, PhD Robert G. Gish, MD Nancy Reau, MD Stefan Zeuzem, MD Released: July 15, 2021

CCO downloadable slides from Dr. Tatyana Kushner providing insights on updated guidance for HCV screening and management in women of childbearing age

Tatyana Kushner, MD, MSCE Released: January 8, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue